Dietary or metabolic endotoxemia is a condition that affects approximately 1/3 of individuals living in Western society. It is characterized by increased serum endotoxin concentration during the first five hours of the post-prandial period following consumption of a meal with a high-fat, high-calorie content. Long-term repeated dietary endotoxemia may increase the risk of developing a variety of chronic diseases. Of the available treatments, oral probiotic supplementation has been purported to reduce gastrointestinal permeability to endotoxin, which in theory should suppress the dietary endotoxin response. The purpose of this study was to determine if 30-d of oral probiotic supplementation could reduce post-prandial dietary endotoxemia in “responder” subjects. Apparently healthy men and women (N=75) were screened for post-prandial dietary endotoxemia. Subjects whose serum endotoxin concentration increased by at least 5-fold from pre-meal levels at 5-h post-prandial were considered “responders” and were randomized to receive either placebo (rice flour) or multi-strain probiotic supplement (Bacillus indicus (H36), Bacillus subtilis (H58), Bacillus coagulans, and Bacillus licheniformis, and Bacillus clausii) for 30-d. The dietary endotoxemia test was repeated at the conclusion of the supplementation period. Dietary endotoxin (LAL) and triglycerides (enzymatic) were measured using an automated chemistry analyzer. Serum disease risk biomarkers were measured using bead-based multiplex assays as secondary, exploratory measures. Data were statistically analyzed using repeated measures ANOVA and a P < 0.05. We found that probiotic supplementation was associated with a 42% reduction in endotoxin (P=0.011) and 24% reduction in triglyceride (P=0.004) in post-prandial period Placebo subjects presented with a 36% increase in endotoxin and 5% decrease in triglycerides over the same post-prandial period. We also found that probiotic supplementation was associated with significant post-prandial reductions in IL-12p70 (P=0.017), IL-1β (P=0.020), and ghrelin (P=0.017) compared to placebo subjects. The key findings of the present study, were that oral probiotic supplementation reduced responses that were consistent with “leaky gut syndrome” and transient reductions in chronic/metabolic disease risk.

Biography:
Thomas Bayne is a chiropractic physician who specializes in nutritional therapies and is an international expert in digestive health and detoxification. His philosophy addresses the relationship between structure and function of the human body and how that translates into your best health. He has over 20 years of experience in natural health and medicine. Thomas Bayneʼs passion for holistic medicine led him to Europe, where he had executive roles at two top natural health companies. As international marketing director for one of Europeʼs leading food supplement manufacturers, Dr. Bayneʼs responsibilities included formulating supplements based on specific patient conditions, lecturing on his clinical experiences, research that supported natural medicines and developing educational materials for physicians and pharmacies. He has developed over 35 highly successful and effective products that are sold directly to physicians. Dr. Bayneʼs 20 years of clinical experience combined with his extensive knowledge in product development has led to the development of MegaSporeBiotic^®.